To clarify the optimal cumulative cisplatin dose (CCD) in locoregionally-advanced nasopharyngel carcinoma (NPC) patients receiving induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT). Using the NPC-specific database from the established big-data intelligence platform at Sun Yat-Sen University Cancer Center, with EBV DNA <1000 copy/mL and receiving <3 IC cycles, a higher dose might be necessary.
| INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer with skewed epidemiology, pathology and response to treatment. 1 The highest incidence worldwide is reported among the Cantonese population of Guangdong Province, where rates ranged from 22.2 to 27.2 per 100 000 males and 9.8 to 11.1 per 100 000 females. 2 Radiotherapy (RT) is the primary treatment modality for non-disseminated NPC due to its radiosensitivity and anatomical location.
NPC is also known to be chemosensitive. The integration of cisplatin-based chemotherapy during RT greatly enhances the effects of RT, facilitates local control and improves therapeutic outcomes. 3, 4 Recently, adding induction chemotherapy (IC) before concurrent chemoradiotherapy (CCRT) has been found to greatly improve survival outcomes, and has been increasingly adopted worldwide based on the clinical data from several important large-scale multi-centre phase II-III randomized controlled trials (RCT), which strongly support the application of IC plus CCRT for locoregionally-advanced NPC. [5] [6] [7] [8] [9] The cumulative cisplatin dose (CCD) administered during RT is an important factor in conferring survival benefits. In the majority of RCTs, 100 mg/m 2 cisplatin was administered every 3 weeks during RT. The importance of a third planned cisplatin cycle was first questioned by Ang et al, 10 who reviewed the compliance levels of CCRT in RCT, and found that a substantial fraction of patients failed to receive the third cycle, and a cumulative dose Clinical complete response (cCR) and partial response (cPR) were observed in 11.3% and 79.6% of patients, respectively. 13 Second, patients may be less able to tolerate the subsequent highly intensive CCRT after 2-4 cycles of IC. Data from published RCT showed that 36% of patients could not adhere to the second planned cisplatin, and that 76.7% of patients could not achieve the third. 5 Third, IMRT is superior in the management of local control compared to conventional RT. 14, 15 Given these facts and the current lack of data, the suitability of 200 mg/m 2 CCD as the optimal cutoff value for locoregionally-advanced NPC patients receiving IC plus CCRT in the era of IMRT remains to be elucidated.
Real world data (RWD) are increasingly used to guide clinical practice and assist in the the assessment of the "value" of the intervention, as they are characterized by variety, veracity and are unfiltered compared with RCT data, which can be confounded by the selection of the patient population, rigorous administration and physician preferences. 16, 17 Therefore, RWD represent an important resource in research, and are promising in answering this question.
Using an NPC population from an endemic area, we aimed to clarify the optimal CCD in locoregionally-advanced NPC patients receiving IC plus CCRT.
| MATERIALS AND METHODS

| Patient population and data extraction
The NPC-specific database from the well-established big-data intelligence platform at Sun Yat-Sen University Cancer Centre (SYSUCC) was adopted to identify 2940 patients with histologically-proven, non-disseminated NPC, diagnosed between January 2005 and December 2012. A detailed description of this database is presented in the Appendix S1. Using the search terms "diagnosis," "histology type," "stage classification," "radiotherapy" and "chemotherapy," we 
| Chemotherapy
The concurrent chemotherapy consisted of 40 mg/m 2 cisplatin administered every week for a maximum of 7 cycles, 80 mg/m 2 cisplatin administered every 3 weeks for a maximum of 3 cycles, or 100 mg/m 2 cisplatin administered every 3 weeks for a maximum of clinical target volume (CTV1) and 54-56 Gy/28-33 fractions to the PTV of the low-risk clinical target volume (CTV2).
| Clinical staging, follow up and study endpoint
All patients were restaged according to the 8th edition of the UICC/ AJCC staging system. 18 Patients were followed up from the initiation of the treatment to the day of last examination or death. Details of the pretreatment examinations and follow-up strategies are shown in the Supplementary materials (Appendix S1).
The primary endpoint was overall survival (OS), which was calculated from the date of treatment initiation to death from any cause.
The secondary endpoint was progression-free survival (PFS), defined as the time from treatment initiation to tumor progression or death; distant metastasis-free survival (DMFS) was defined as the time to tumor metastasis; and locoregional relapse-free survival (LRFS) was the time to the first locoregional relapse.
| Study design and statistical analysis
At the time this study was conducted, no data regarding the optimal CCD administered during RT for NPC patients receiving IC plus CCRT were available; however, published data suggested that a CCD confounding factors and to minimize bias with respect to initial treatment selection, 2 well-balanced cohorts were generated through propensity score matching (PSM) analysis in the third step of the study, 19 during which patients without complete data regarding EBV DNA were excluded (n = 111). Finally, subgroup analyses were con- 3 | RESULTS
| Patient characteristics and treatment compliance
The baseline characteristics of 583 eligible patients were presented in Table 1 . The median age at diagnosis was 44 years (range, 18-76 years); 48.5% of subjects were at stage III (n = 283) and 51.5%
were at stage IV (n = 300). In total, 55.9% of patients (n = 326) Table 3 shows all other variables associated with survival endpoints.
| Subgroup analysis
Subgroup analyses were further conducted for OS and PFS, to identify the subgroups that might benefit from the administration of higher cisplatin dose after IC. We found that there were no interactions between clinicopathologic variables and 160 mg/m 2 CCD with respect to OS ( Figure 5A ). However, interactions of 160 mg/m 2 CCD with pretreatment EBV DNA and IC cycles were observed with respect to PFS (P interaction = 0.04; Figure 5B ). In the subgroup of patients with pretreatment EBV DNA <1000 copies/mL, administration of CCD > 160 mg/m 2 tended to yield favorable prognosis (HR = 0.26; 95% CI: 0.07-0.93, P = .03), while the survival benefit was not observed in patients with pretreatment EBV DNA > 1000 copies/mL (HR = 1.12; 95% CI: 0.69-1.82, P = .64). In addition, there was potentially greater benefit for the subgroup of patients who received In addition, subgroup analysis demonstrated potentially favorable PFS, but not OS, in patients with pretreatment EBV DNA < 1000 copies/mL, and <3 cycles of IC with higher cisplatin administration.
In the present study, 200 mg/m 2 CCD did not yield significant improvements in survival outcomes in patients with locoregionallyadvanced NPC receiving IC plus CCRT, while 160 mg/m 2 CCD might be enough to yield beneficial antitumor effects. This is in accordance with previously published reports. 11, 12, 21 In the combined analyses of 2 prospective trials, NPC-9901 and NPC-9902, 21 a total dose of cisplatin during the concurrent phase (>200 mg/m 2 ) had a significant impact on LRFS and OS in the In addition to the influence of pretreatment EBV DNA, IC cycles also modified the prognostic effect of CCD. Previous studies showed that there was no difference in survival between patients receiving 2 cycles of IC and patients receiving >2 cycles of IC, when the CCRT regimens and cycles were well-balanced between groups. 27 Our results shed light on the previous findings The following parameters were included in the Cox proportional hazards model multivariate analysis: cumulative cisplatin dose (CCD > 160 mg/ m 2 vs CCD < 160 mg/m 2 ); IC cycles (>2 cycles vs 2 cycles); IC regimens (TPF vs TP vs PF vs others); age (>66 vs 45-65 vs <45 years); sex (female vs male); year of diagnosis (2011-2013 vs 2005-2010) ; tumor category (T3-4 vs T1-2); node category (N2-3 vs N0-1) and pretreatment Epstein-Barr virus DNA (≥1000 copies/mL vs <1000 copies/mL). platinum-based; moreover, the propensity-matched analysis was applied to create well-balanced groups and to reduce the bias.
In conclusion, the causal relationship between 200 mg/m 2 CCD and improvement in survival outcomes was not defined in locoregionally-advanced NPC patients receiving IC plus CCRT, and our results indicated that 160 mg/m 2 CCD might be sufficient to yield beneficial antitumor effects in IC. However, higher doses of cisplatin delivered during RT are required to achieve beneficial effects in patients with pretreatment EBV DNA <1000 copies/mL and receiving <3 cycles of IC.
ACKNOWLEDGMENTS
We thank the staff members at Caradigm and Yiducloud (Beijing)
technology for their asisstance with establishment of the big-data intelligence platform for cancer research in our cancer centre. We are also grateful for their help with data mining, extraction and processing.
DISCLOSURE STATEMENT
The authors have no conflict of interest to declare.
O R C I D
Ying Sun http://orcid.org/0000-0002-5888-2929
